5 Stocks With Easy Double-Digit Returns

3. Liquidia Corp. (NASDAQ:LQDA)

Liquidia climbed to a fresh all-time high on Monday, as investors took heart from its stellar earnings performance in the first quarter of the year, thanks to strong sales from its pulmonary hypertension treatment, Yutrepia.

In intra-day trading, the stock surged to its highest price of $53.93 before trimming gains to end the session just up by 25.35 percent at $53.13 apiece.

In an updated report, Liquidia Corp. (NASDAQ:LQDA) said that it swung to a net income of $52.86 million in the first quarter of the year from a $38.4 million net loss in the same period in 2025, marking its third quarter of swing to profitability, amid a strong uptake for Yutrepia.

Total revenues soared by 4,328 percent to $132.86 million from only $3.12 million in the same comparable period. Of the total, product sales amounted to $129.9 million, while service revenues finished at $3 million.

As of April 30, 2026, Liquidia Corp. (NASDAQ:LQDA) said that Yutrepia has received more than 4,500 unique patient prescriptions since its launch in June 2025, with prescription-to-start conversion remaining strong at 85 percent.

“Yutrepia continued to demonstrate sustained uptake in pulmonary arterial hypertension and pulmonary hypertension associated with interstitial lung disease (PH-ILD), consistent with its growing adoption as the preferred inhaled prostacyclin of choice. Having initiated additional Phase 4 studies of Yutrepia and our pivotal Phase 3 Re-Spire study of L606, our focus in 2026 is on making the full benefit of prostacyclin therapy available to more patients who need it, across a broader set of serious pulmonary and vascular diseases where high unmet need remains prevalent,” said Liquidia Corp. (NASDAQ:LQDA) CEO Roger Jeffs.